login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Genous stent is a safe and effective option in STEMI patients


Friday, 09 Mar 2012 09:26
Genous
Genous

OrbusNeich has reported clinical data showing that the Genous stent is safe and effective for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Published in Revista Española de Cardiología, the data from the GENIA study show low rates of stent thrombosis and target lesion revascularisation at a mean follow-up of 538 ± 334.72 days.


In the prospective observational study, which included 139 consecutive patients undergoing primary angioplasty with implantation of one or more Genous stents, the target lesion revascularisation rate was 3.8% and the rate of definite stent thrombosis was 1.4%. In addition, the rate of cardiac death was 2.9% (four patients), and the target vessel revascularisation was 5.8%.


“STEMI is a highly prothrombotic clinical situation for which the choice of the most appropriate stent remains controversial,” said Melisa Santas-Alvarez, Departamento de Cardiología Intervencionista, Hospital Clínico de Santiago de Compostela, Spain, and first author of the study. “In high-risk situations like STEMI, drug eluting stents can delay healing of the vessel and have been associated with increased risk of thrombosis. We believe that the Genous stent’s ability to accelerate endothelialisation may reduce the risk of stent thrombosis. These results add to the growing body of knowledge confirming the safety and efficacy of Genous in STEMI patients.”


In the GENIA study, the average patient age was 64 ± 13.5 years, and 74.8% of patients were male. Notably, 20.1% of patients had multivessel disease. Patients were prescribed a regimen of antithrombotic and anticoagulant therapy in accordance with the European guidelines for the management of acute myocardial infarction.





Add New Comment

Related Items


Most popular


First patient enrolled in Vessix sham-controlled study
Friday, 17 Apr 2015
Boston Scientific has announced that it is taking a new approach to evaluate the performance of its Vessix renal Denervation System. It says it is initiating a study with a novel design to isolate ... First patient enrolled in Vessix sham-controlled study

CardioCel to feature at prominent heart valve conferences
Wednesday, 01 Apr 2015
Admedus’ CardioCel will be featured in a number of presentations at the American Association for Thoracic Surgery Mitral Conclave 2015 meeting and the 95th AATS Annual Meeting. CardioCel to feature at prominent heart valve conferences

Medtronic initiates study evaluating potential of combination of pulmonary vein isolation and renal denervation for atrial fibrillation
Friday, 01 May 2015
Medtronic has announced the start of a clinical study using Medtronic technologies to determine whether paroxysmal and persistent atrial fibrillation can be treated with a combination of two ablation ... Medtronic initiates study evaluating potential of combination of pulmonary vein isolation and renal denervation for atrial fibrillation

Features


Tips and tricks for achieving optimum results with a drug-coated balloon
Thursday, 07 May 2015
With drug-coated balloons, we may have been able to deliver a device to the lesion, but we were not always sure how much drug we actually delivered. Fortunately, because of this problem, there have ... Tips and tricks for achieving optimum results with a drug-coated balloon

Robotic PCI could be used to reduce radiation exposure to the operator
Thursday, 09 Apr 2015
Ryan Madder, an interventional cardiologist at the Frederik Meijer Heart & Vascular Institute (Spectrum Health, Grand Rapids, Michigan, USA) explains why he believes a robotic system (CorPath, C... Robotic PCI could be used to reduce radiation exposure to the operator

Profiles


Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions